Regardless of the sequential decrease in Current Liabilities, during the second quarter 2026, Quick Ratio deteriorated to 3 below Qc Technologies Inc 's average Quick Ratio.

Within In Vitro & In Vivo Diagnostic Substances industry 3 other companies have achieved higher Quick Ratio than Qc Technologies Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 747 to 1117.

Explain Quick Ratio?
How much Cash & cash equivalents QCLS�s has?
What are QCLS�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

QCLS Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	-33.9 %	-25.25 %	-17.45 %	-11.1 %	-4.02 %
Y / Y Cash & cash equivalent Change	188.15 %	120.72 %	85.35 %	-6.07 %	-70.82 %
Quick Ratio MRQ	3	3.52	2.85	1.61	0.69
QCLS's Total Ranking	# 1117	# 747	# 0	# 1205	# 0
Seq. Current Liabilities Change	-0.57 %	-33.31 %	-10.72 %	11.64 %	12.44 %
Seq. Cash & cash equivalent Change	-15.32 %	-17.82 %	57.95 %	162.15 %	-35.14 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 4
Healthcare Sector	# 405
Overall Market	# 1117

Quick Ratio Statistics
High	Average	Low
13.57	4.22	0.07
(Mar 31 2014)		(Sep 30 2017)

Financial Statements
Qc Technologies Inc 's Current Liabilities	$ 4 Millions	Visit QCLS's Balance sheet
Qc Technologies Inc 's Cash & cash equivalent	$ 11 Millions	Visit QCLS's Balance sheet
Source of QCLS's Sales		Visit QCLS's Sales by Geography

Cumulative Qc Technologies Inc 's Quick Ratio

QCLS's Quick Ratio for the trailling 12 Months

QCLS Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-20.99 %	-14.03 %	-5.03 %	7.87 %	18.4 %
Y / Y Cash & cash equivalent TTM Growth	72.42 %	11.72 %	4.46 %	-7.11 %	2.32 %
Quick Ratio TTM	2.61	2.03	1.6	1.21	1.19
Total Ranking TTM	# 4046	# 2809	# 0	# 2451	# 0
Seq. Current Liabilities TTM Growth	-8.97 %	-5.61 %	-5 %	-3.2 %	-0.95 %
Seq. Cash & cash equivalent TTM Growth	16.85 %	20 %	25.77 %	-2.24 %	-24.28 %

Quick ratio ranking by company, industry and sector >> Back to QCLS Financial Strength Comparisons >> Go to Compare QCLS Quick Ratio to its Competitors

On the trailing twelve months basis QCLS Cash & cash equivalent more than doubled by 188.15 % in Q2 2026 year on year, while Current Liabilities decreased to $4 millions, this led to increase in in Qc Technologies Inc 's Quick Ratio to 2.61, above QCLS average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 14 other companies have achieved higher Quick Ratio than Qc Technologies Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2809 to 4046.

Explain Quick Ratio?
How much Cash & cash equivalents QCLS�s has?
What are QCLS�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the In Vitro & In Vivo Diagnostic Substances Industry	# 15
Healthcare Sector	# 902
Within the Market	# 4046

trailing twelve months Quick Ratio Statistics
High	Average	Low
3.23	0.53	0.07
(Sep 30 2020)		(Jun 30 2025)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within In Vitro & In Vivo Diagnostic Substances Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Intellia Therapeutics Inc	5.51	$ 437.759 Millions	$ 79.392 Millions
Qc Technologies Inc	3.00	$ 10.987 Millions	$ 3.669 Millions
Alpha Teknova Inc	2.54	$ 17.436 Millions	$ 6.872 Millions
Lantheus Holdings Inc	1.77	$ 593.298 Millions	$ 335.677 Millions
Insight Molecular Diagnostics Inc	1.73	$ 17.756 Millions	$ 10.286 Millions
Achieve Life Sciences Inc	1.65	$ 326.645 Millions	$ 197.657 Millions
Immucell Corporation	1.51	$ 8.860 Millions	$ 5.863 Millions
Myriad Genetics Inc	0.88	$ 115.200 Millions	$ 130.700 Millions

Date modified: 2026-09-04T07:58:58+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.